<?xml version="1.0"?>
<notificationOfRemoval>

    <schemaVersion>X0203</schemaVersion>

    <exchange>
        <cik>0001143313</cik>
        <entityName>NYSE AMERICAN LLC</entityName>
    </exchange>

    <issuer>
        <cik>0000810509</cik>
        <entityName>NAVIDEA BIOPHARMACEUTICALS, INC.</entityName>
        <fileNumber>001-35076</fileNumber>
        <address>
            <street1>5600 Blazer Parkway, Suite 200</street1>
            <city>Dublin</city>
            <stateOrCountryCode>OH</stateOrCountryCode>
            <stateOrCountry>OHIO</stateOrCountry>
            <zipCode>43017-7550</zipCode>
        </address>
        <telephoneNumber>(614) 793-7500</telephoneNumber>
    </issuer>

    <descriptionClassSecurity>Preferred Stock Purchase Rights</descriptionClassSecurity>

    <ruleProvision>17 CFR 240.12d2-2(b)</ruleProvision>

    <signatureData>
        <signatureName>Nicolas Connolly</signatureName>
        <signatureTitle>Analyst, Regulation</signatureTitle>
        <signatureDate>2024-01-16</signatureDate>
    </signatureData>
</notificationOfRemoval>